KMCRIC

Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.

Breast Cancer Res Treat.

2016

156(3)

453-64.

10.1007/s10549-016-3759-2.

27013473

http://www.ncbi.nlm.nih.gov/pubmed/27013473

Adult
Aged
Breast Neoplasms/drug therapy*
Breast Neoplasms/ethnology
Breast Neoplasms/pathology*
Bridged-Ring Compounds/adverse effects*
Bridged-Ring Compounds/therapeutic use
Double-Blind Method
Electroacupuncture/methods*
Female
Humans
Middle Aged
Peripheral Nervous System Diseases/chemically induced
Peripheral Nervous System Diseases/prevention & control*
Pilot Projects
Taxoids/adverse effects*
Taxoids/therapeutic use
Treatment Outcome

Acupuncture; Breast cancer; Chemotherapy-induced peripheral neuropathy; Electro-acupuncture; Taxane

침 치료; 유방암; 항암화학요법에 의한 말초 신경병증; 전침; 탁산

KMCRIC 비평 보기 +

To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN.

영어